The Eye Institute is proud to announce the arrival of Valeda™, a revolutionary, FDA-approved therapy for the treatment of dry age-related macular degeneration (AMD), now available to patients in Rapid City. This state-of-the-art technology utilizes photobiomodulation (PBM) to target the root causes of the disease at the cellular level, offering new hope for patients managing this progressive eye condition.
Valeda is the first approved light-based therapy designed to treat dry AMD. It works by delivering precise wavelengths of red and near-infrared light to stimulate mitochondrial function, enhance cellular metabolism, reduce inflammation, and slow retinal degeneration. This advanced treatment may improve vision and help reduce drusen—yellow deposits in the retina that are characteristic of dry AMD.
Clinical studies have shown compelling benefits. In the LIGHTSITE III trial, patients treated with PBM therapy experienced:
- Improvement in visual acuity, with an average gain of more than one line on the eye chart after one and two years of treatment.
- Reduction in drusen volume, the macular deposits that contribute to vision loss.
- Prevention of geographic atrophy progression, with a significant reduction in the development of this condition in treated patients compared to those who received a sham treatment.
"These results are exciting as they provide a means to maintain vision and slow the progression of dry AMD," said Dr. Prema Abraham of The Eye Institute. "We are thrilled to offer this innovative therapy to our community and bring new possibilities for preserving sight."
Valeda therapy is now available at The Eye Institute. To learn more or schedule a consultation, please contact the Eye Institute at 605-341-2000.
Source: Content and Information Regarding Valeda https://myvaleda.com/
Disclaimer: This article is designed for educational purposes only and does not render medical advice or professional services. The information provided through this should not replace consulting a medical professional.